0001415889-22-000401.txt : 20220105 0001415889-22-000401.hdr.sgml : 20220105 20220105200014 ACCESSION NUMBER: 0001415889-22-000401 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Trachtenberg Eric CENTRAL INDEX KEY: 0001646300 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 22513257 MAIL ADDRESS: STREET 1: 1414 RALEIGH ROAD STREET 2: SUITE 400 CITY: CHAPEL HILL STATE: NC ZIP: 27517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 4 1 form4-01052022_080105.xml X0306 4 2022-01-03 0001479419 Kala Pharmaceuticals, Inc. KALA 0001646300 Trachtenberg Eric C/O KALA PHARMACEUTICALS, INC. 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 false true false false SEE REMARKS Common Stock 2022-01-04 4 S 0 2850 1.30 D 113816 D Stock Option (right to buy) 1.37 2022-01-03 4 A 0 153000 0 A 2032-01-03 Common Stock 153000 153000 D This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes 53,611 unvested RSUs. This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. General Counsel, Chief Compliance Officer and Secretary /s/ Eric Trachtenberg 2022-01-05